epilepsy DISORDERS
Epilepsy Drug Discovery:
Cracking the Pharmacoresistance Code
Epileptic disorders are chronic neurological conditions characterized by recurrent epileptic seizures or spontaneous epileptiform events, resulting from the hypersynchrony and hyperexcitability of one or more neural networks.
For the discovery of new AntiSeizure Medications (ASMs) to treat epileptic disorders, the main challenge is to solve the problem of drug resistance, which affects around 30% of patients. Thus, researchers not only have to deal with the significant side effects of current anti-epileptic drugs, the limited predictive value of existing preclinical models, the lack of treatments targeting epileptogenesis rather than simply suppressing symptoms, and the need for a multidisciplinary approach to drug development, but also complex resistance mechanisms and heterogeneity among drug-resistant patients.
To meet these challenges, new approaches are being explored. More complex animal models hold a key place in this exploration, allowing researchers to screen for more effective treatments that tackle the underlying mechanisms of epilepsy and overcome the problem of drug resistance.
Preclinical Epilepsy: Matching Relevant Models and EEG Biomarkers to Epilepsy Types Is Crucial for Effective ASMs Discovery
SynapCell, as a preclinical CRO, was a pioneer in the development of preclinical EEG dedicated to drug discovery. Our historic area of expertise is Epilepsy; over the last decade we diversified into other therapeutic areas. We now have 20 years’ experience in preclinical EEG in the field of Epilepsy, and have never stopped making progress.
Combining relevant animal models for each type of Epilepsy and predictive translational EEG biomarkers is what makes our approach unique. We can thus provide drug developers with high-quality information and decision-making capabilities to identify and test their most promising drug candidates in order to accelerate the discovery of new antiseizure medications.
Not all of the available Epilepsy models are equal. For effective ASMs discovery, it is essential to use the right translational model for each type of Epilepsy together with its related EEG biomarker. This is where SynapCell comes in!
Why Preclinical EEG?
EEG is the gold standard for all epilepsy-related tests, providing reliable, objective measurements of the brain’s electrical activity. At SynapCell, we record epileptiform events using translational in vivo electrophysiology methods to measure electrical activity in the brains of translational free-moving rodent models of Epilepsy.
Adopt the Right Model for Each Type of Epilepsy...
For optimal results, we develop or use specific models (MTLE, Amygdala-Kindling, and GAERS models) mimicking specific Epilepsy types. All our models are: translational –perfectly mirroring the corresponding human condition, stable over time, and validated with a reference pharmacology acting on specific EEG biomarkers.
...With the Right Predictive EEG Biomarkers
Inspired by clinical research on patients, SynapCell has developed a translational EEG biomarker for each specific model.
Drug discoverers can thus test a compound’s efficacy and side effects as well as its impact on the brain at the preclinical stage. The results obtained show excellent predictivity for later clinical phases.
Explore our Programs for Epilepsy Disorders
The pharmaceutical industry is developing novel therapies thanks to technological advances, from small molecules to new approaches, such as gene or cell therapies. SynapCell helps you to get ready to tackle these new opportunities in the field of Epilepsy!
Your Preclinical and Clinical Roadmaps Aligned
Novel AntiSeizure Medications (ASMs) must treat both Focal (partial) Epilepsy and Generalized (Absence) seizures and be better than the existing standard of care. SynapCell has translational and non-convulsive animal models for both these applications, allowing you to align your preclinical and clinical roadmaps with the support of an experienced partner.
Beyond Epilepsy
Today, Antiseizure Medications (ASMs) are being used for indications beyond Epilepsy, to treat various brain disorders. For example, Gabapentin or Primidone, originally developed for Epilepsy, are also used to treat Essential Tremor. Looking to explore new opportunities and fields of application for your compounds?
“We had set a very high internal bar going into the project, and the team at SynapCell provided excellent support and guidance throughout the entire process. In the end, the project was a great success thanks to their expertise, dedication and professionalism. It’s clear why SynapCell has such an exceptional reputation, and we will think of them first for future preclinical epilepsy studies.”
James Stewart, Scientist at Ventus Therapeutics.
Powered by Cue®, SynapCell's Predictive In Vivo EEG Platform
SynapCell’s specific models for Epilepsy and their associated EEG biomarkers are processed on Cue®, our innovative translational in vivo EEG platform, which is designed to predict the in-human efficacy of your drug candidates during the preclinical step. Cue® is the result of decades of R&D, combining SynapCell’s know-how, expertise and scientific excellence in the fields of brain surgery and EEG signal recording, processing, and analysis.
Using Cue®, we transform preclinical data into actionable insights, offering end-to-end support for informed decision-making in CNS drug discovery.
Let's Talk About Your Research Project!
More than a CRO, a team of collaborators – we are your dream neuroscience team specialized in preclinical EEG! We don’t just produce data, we are your partners from conceptualization to conclusion. We translate raw EEG data into meaningful, clinically-relevant endpoints, delivering clear insights to allow data-based decision-making. Choose SynapCell, a leading preclinical CNS-specialized CRO for cutting-edge EEG expertise combined with an irresistible touch of fun.
News & Events